United States District Court upholds validity of Lilly's Evista patents through 2014.
"We are pleased with the court's rulings on Evista's method-of-use patents. We have always been very confident that these patents are valid and enforceable and today's court ruling sends a clear message on the strength of those patents," said Robert A. Armitage, senior vice president and general counsel for Lilly. "Protection of intellectual property rights is extremely important to the biopharmaceutical industry and the physicians and patients we serve, as these rights help support the development of the next generation of innovative medicines to treat unmet medical needs."
In addition, the Court held Lilly's Evista particle-size patents invalid. The company is reviewing this aspect of the ruling to determine whether or not to appeal.
Evista is a medicine indicated for the treatment and prevention of osteoporosis in postmenopausal women; and the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis and the reduction in risk of invasive breast cancer in postmenopausal women at high risk for invasive breast cancer.
Lilly is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations.
Eli Lilly and Company
|Printer friendly Cite/link Email Feedback|
|Publication:||BIOTECH Patent News|
|Date:||Aug 1, 2009|
|Previous Article:||Oxygen Biotherapeutics, Inc. files patent application for emergency heart attack treatment device.|
|Next Article:||Brinks Hofer Gilson & Lione wins patent appeal for Cook Incorporated Federal Circuit holds that Cook's Endovascular graft devices do not infringe.|